TFPI and thrombophilia: While the clinical relevance of factor V Leiden (F5) (leading to hypercoagulability due to a reduced ability of factor V variant degradation) and prothrombin (F2) 20210G>A mutation (leading to increased levels of prothrombin possibly due to increased pre-mRNA stability) has been extensively characterized, the effect of other so-called thrombophilic risk factors, e.g., affecting β-fibrinogen (FGB) or tissue-factor-pathway-inhibitor (TFPI) is largely unknown.